Persones / Equip Humà

F. Xavier Palomer Tarridas

Buscador de publicacions

Publicacions

  • Montori M, Aguilar-Recarte D, Zarei M, Pizarro J, Palomer FX and Vazquez M.

    Endoplasmic reticulum stress downregulates PGC-1 alpha in skeletal muscle through ATF4 and an mTOR-mediated reduction of CRTC2

    CELL COMMUNICATION AND SIGNALING . 20(1): 53-53. Nº de cites: 9

    [doi:10.1186/s12964-022-00865-9]

  • Aguilar-Recarte D, Barroso E, Gumá L, Pizarro J, Peña L, Ruart M, Palomer FX, Wahli W and Vazquez M.

    GDF15 mediates the metabolic effects of PPARß/d by activating AMPK.

    CELL REPORTS . 36(6): 109501-109501. Nº de cites: 28

    [doi:10.1016/j.celrep.2021.109501]

  • Aguilar-Recarte D, Palomer FX, Wahli W and Vazquez M.

    The PPARß/d-AMPK Connection in the Treatment of Insulin Resistance.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 22(16): 8555. Nº de cites: 12

    [doi:10.3390/ijms22168555]

  • Palomer FX, Aguilar-Recarte D, García R, Nistal JF and Vazquez M.

    Sirtuins: To Be or Not To Be in Diabetic Cardiomyopathy.

    TRENDS IN MOLECULAR MEDICINE . 27(6): 554-571. Nº de cites: 17

    [doi:10.1016/j.molmed.2021.03.004]

  • Aguilar-Recarte D, Palomer FX and Vazquez M.

    Uncovering the role of apolipoprotein C-III in insulin resistance

    Clinica e Investigacion en Arteriosclerosis . 33(2): 108-115. Nº de cites: 1

    [doi:10.1016/j.arteri.2020.09.003]

  • Zarei M, Aguilar-Recarte D, Palomer FX and Vazquez M.

    Revealing the role of peroxisome proliferator-activated receptor beta/delta in nonalcoholic fatty liver disease

    METABOLISM-CLINICAL AND EXPERIMENTAL . 114: 154342-154342. Nº de cites: 21

    [doi:10.1016/j.metabol.2020.154342]

  • Barroso E, Rodríguez-Rodríguez R, Zarei M, Pizarro-Degado J, Planavila A, Palomer FX, Villarroya-Gombau F and Vazquez M.

    SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1 alpha-LIPIN 1 pathway and increasing CD36 through Nrf2

    CELL COMMUNICATION AND SIGNALING . 18(1): 147-147. Nº de cites: 18

    [doi:10.1186/s12964-020-00640-8]

  • Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis

    TRENDS IN PHARMACOLOGICAL SCIENCES . 41(3): 199-208. Nº de cites: 52

    [doi:10.1016/j.tips.2019.12.005]

  • Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya-Gombau F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M.

    SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.

    signal transduction and targeted therapy . 5(1): 14-14. Nº de cites: 77

    [doi:10.1038/s41392-020-0114-1]

  • Zarei M, Pujol E, Quesada T, Villarroya-Gombau F, Barroso E, Vázquez S, Pizarro J, Palomer FX and Vazquez M.

    Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

    BRITISH JOURNAL OF PHARMACOLOGY . 176(13): 2292-2305. Nº de cites: 13

    [doi:10.1111/bph.14678]